| SOCIÉ, Gérard, Claudia SCHMOOR, Wolfgang A. BETHGE, Hellmut D. OTTINGER, Matthias STELLJES, Axel R. ZANDER, Liisa VOLIN, Tapani RUUTU, Dominik A. HEIM, Rainer SCHWERDTFEGER, Karin KOLBE, Jiří MAYER, Johan A. MAERTENS, Werner LINKESCH, Ernst HOLLER, Vladimir KOZA, Martin BORNHÄUSER, Hermann EINSELE, Hans-Jochem KOLB, Hartmut BERTZ, Matthias EGGER, Olga GRISHINA a Jürgen FINKE. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Online. Blood. 2011, roč. 117, č. 23, s. 6375-6382. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2011-01-329821. [citováno 2024-04-24] |
Další formáty:
BibTeX
LaTeX
RIS
@article{945555,
author = {Socié, Gérard and Schmoor, Claudia and Bethge, Wolfgang A. and Ottinger, Hellmut D. and Stelljes, Matthias and Zander, Axel R. and Volin, Liisa and Ruutu, Tapani and Heim, Dominik A. and Schwerdtfeger, Rainer and Kolbe, Karin and Mayer, Jiří and Maertens, Johan A. and Linkesch, Werner and Holler, Ernst and Koza, Vladimir and Bornhäuser, Martin and Einsele, Hermann and Kolb, HansandJochem and Bertz, Hartmut and Egger, Matthias and Grishina, Olga and Finke, Jürgen},
article_number = {23},
doi = {http://dx.doi.org/10.1182/blood-2011-01-329821},
keywords = {BONE-MARROW-TRANSPLANTATION; CONSENSUS DEVELOPMENT PROJECT; MATCHED UNRELATED DONORS; WORKING GROUP-REPORT; FOLLOW-UP; ANTITHYMOCYTE GLOBULIN; CLINICAL-TRIALS; COMPETING RISKS; DEPLETION; SURVIVAL},
language = {eng},
issn = {0006-4971},
journal = {Blood},
title = {Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.},
volume = {117},
year = {2011}
}
TY - JOUR
ID - 945555
AU - Socié, Gérard - Schmoor, Claudia - Bethge, Wolfgang A. - Ottinger, Hellmut D. - Stelljes, Matthias - Zander, Axel R. - Volin, Liisa - Ruutu, Tapani - Heim, Dominik A. - Schwerdtfeger, Rainer - Kolbe, Karin - Mayer, Jiří - Maertens, Johan A. - Linkesch, Werner - Holler, Ernst - Koza, Vladimir - Bornhäuser, Martin - Einsele, Hermann - Kolb, Hans-Jochem - Bertz, Hartmut - Egger, Matthias - Grishina, Olga - Finke, Jürgen
PY - 2011
TI - Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
JF - Blood
VL - 117
IS - 23
SP - 6375-6382
EP - 6375-6382
SN - 00064971
KW - BONE-MARROW-TRANSPLANTATION
KW - CONSENSUS DEVELOPMENT PROJECT
KW - MATCHED UNRELATED DONORS
KW - WORKING GROUP-REPORT
KW - FOLLOW-UP
KW - ANTITHYMOCYTE GLOBULIN
KW - CLINICAL-TRIALS
KW - COMPETING RISKS
KW - DEPLETION
KW - SURVIVAL
N2 - Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P =.47, and HR = 0.68, P =.18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P =.39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P <.0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity.
ER -
SOCIÉ, Gérard, Claudia SCHMOOR, Wolfgang A. BETHGE, Hellmut D. OTTINGER, Matthias STELLJES, Axel R. ZANDER, Liisa VOLIN, Tapani RUUTU, Dominik A. HEIM, Rainer SCHWERDTFEGER, Karin KOLBE, Jiří MAYER, Johan A. MAERTENS, Werner LINKESCH, Ernst HOLLER, Vladimir KOZA, Martin BORNHÄUSER, Hermann EINSELE, Hans-Jochem KOLB, Hartmut BERTZ, Matthias EGGER, Olga GRISHINA a Jürgen FINKE. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Online. \textit{Blood}. 2011, roč.~117, č.~23, s.~6375-6382. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2011-01-329821. [citováno 2024-04-24]
|
